chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This case was reported by a physician via a sales representative and described the occurrence of chronic hepatitis B in a 22-year-old male subject who was vaccinated with hepatitis B vaccine (manufacturer unspecified). On unspecified dates as a child, the subject received a hepatitis B vaccine series (the total number of doses received and the schedule for immunization was not reported). In 2011, within years of vaccination with Hepatitis B vaccine, the subject "contracted" chronic hepatitis B. The specific date of onset was not known, but was picked up on a hepatitis panel (date not provided). The physician conveyed that this could be possible vaccination failure. No other events were reported. The physician considered the events were clinically significant (or requiring intervention). At the time of reporting the events were unresolved. The physician considered the events were possibly related to vaccination with Hepatitis B vaccine. It was additionally reported that the subject's 18 year old brother also contracted hepatitis B following a hepatitis B series as a child. The brother's case number is A0954197A. All other members of the subjects family including the mother, father, and sister were negative for hepatitis B.
Information has been received from a nurse referring to a patient of unknown age and gender. The patient's medical history, concurrent condition and concomitant therapy were not reported. On an unknown date, the patient was vaccinated with improper stored VARIVAX (lot# N034559, expiration date: 05-DEC-2019, strength, dose, frequency and route were unknown) for prophylaxis reconstituted with well stored sterile diluent (Product storage error). The vaccines had temperature excursion of 15 degree F to 46 degree F (18.9F) for 7 hours 18 minutes. Previous temperature excursion was 15 degree F to 46 degree F (14.5 F) for 48 minutes. The call was due to the digital data logger. No adverse event was reported. No product quality compliant involved.
Arm was swollen; woke up with terrible chills that lasted 45-60 minutes; Her arm was sore; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (Her arm was sore), PERIPHERAL SWELLING (Arm was swollen) and CHILLS (woke up with terrible chills that lasted 45-60 minutes) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Jan-2021, the patient experienced ARTHRALGIA (Her arm was sore). On 18-Jan-2021, the patient experienced PERIPHERAL SWELLING (Arm was swollen) and CHILLS (woke up with terrible chills that lasted 45-60 minutes). At the time of the report, ARTHRALGIA (Her arm was sore), PERIPHERAL SWELLING (Arm was swollen) and CHILLS (woke up with terrible chills that lasted 45-60 minutes) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided.  No concomitant medication was provided.
This is a spontaneous report received from a contactable reporter(s) (Nurse) from medical information team. An adult female patient received BNT162b2 (BNT162B2), as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (First Booster dose, UNKNOWN MANUFACTURER), for COVID-19 immunization; Covid-19 vaccine (Primary Immunization series complete; UNKNOWN MANUFACTURER), for COVID-19 immunization. The following information was reported: RASH PRURITIC (non-serious), 3 days after the suspect product(s) administration, outcome "unknown", described as "Diffused, systemic, itchy rash". Additional information: Reporter asked if there is any reports for Pfizer covid-19 vaccine of a diffused itchy rash in patient over 55 years of age. Patient's developed a systemic rash potentially within 3 days of getting the Pfizer COVID-19 Vaccine.  It is not at the injection site, but all over.
pruritic rash; This is a spontaneous report from a contactable other-health care professional. A female patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Batch/Lot number was not reported), dose 1 via an unspecified route of administration on an unspecified date as dose 1, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. On an unspecified date, the patient experienced pruritic rash. Reporter requesting if this was a severe allergic reaction and patient did not have hives, no wheezing, no angioedema and no anaphylaxis and asks, since the symptoms did not present in a few minutes would this be considered a severe allergic reaction, and also can this patient receive second dose under supervision or should she not receive it at all. The outcome of the event was unknown.  No follow-up attempts are needed. No further information is expected.
My legs were cramping, my whole body was shaky.  My face felt like it was burning up.  I felt really weak, no energy.
For 4hs she experienced vertigo and dizziness; For 4hs she experienced vertigo and dizziness; Vomiting; This spontaneous case was reported by a consumer and describes the occurrence of VERTIGO (For 4hs she experienced vertigo and dizziness), DIZZINESS (For 4hs she experienced vertigo and dizziness) and VOMITING (Vomiting) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027a21a) for COVID-19 vaccination.     The patient's past medical history included Vertigo (for shorter periods (1 minute)). Concomitant products included METOPROLOL, ATORVASTATIN and ASPIRIN [ACETYLSALICYLIC ACID] for an unknown indication.    On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Mar-2021, the patient experienced VERTIGO (For 4hs she experienced vertigo and dizziness), DIZZINESS (For 4hs she experienced vertigo and dizziness) and VOMITING (Vomiting). The patient was treated with MECLIZINE [MECLOZINE] at a dose of 25 mg once a day. On 05-Mar-2021, VERTIGO (For 4hs she experienced vertigo and dizziness), DIZZINESS (For 4hs she experienced vertigo and dizziness) and VOMITING (Vomiting) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
pt recv vax 14MAY97 & noted swelling & redness on upper arm & mild tenderness noted w/small induration around site;
The patient repeorts that after recieving her flu vaccine, she is still cannot move her arm due to the pain in her arm 10 days later.
vaccinated with vaccines that were in the fridge for 33 days; This spontaneous case was reported by a consumer and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vaccinated with vaccines that were in the fridge for 33 days) in a 40-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 29-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Jun-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (vaccinated with vaccines that were in the fridge for 33 days). On 22-Jun-2021, EXPIRED PRODUCT ADMINISTERED (vaccinated with vaccines that were in the fridge for 33 days) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication details was reported. No treatment medication details was reported.
Information has been received form a physician concerning a female in her early 20's who was vaccinated with the first dose of GARDASIL. Shortly after the vaccine was given, the patient experienced pain and swelling at the injection site. Subsequently, the patient recovered from the events. Additional information has been requested.
Bad rash all over body . Very itchy been almost 5 weeks now . Took topicals  did not work. Doctor prescribed prednisone. Cleared up alittle need to do another refill of prednisone in hopes it will clear up.
pt recvd vax & exp elevated liver function test & malaise; pt indicated never since 1976 have liver enzymes elevated to this degree; pt's period of total disability was 9APR93 to 25OCT93;
Fever >102, vomiting, diarrhea, fussiness, rash x 72hrs. Began about 6 hours after vaccine admin. Vomiting continued for an additional 4 days (still vomiting, not yet subsided). Treatment- seen by pediatrician on day 7. Continue to monitor.
2.5 days after receiving the Moderna Booster dose, I woke up with severe and sharp chest pains on the left side of my chest. Went to the Emergency Room within 2 hours and was diagnosed with pericarditis.
3-5 min episode of being limp & unable to arouse day p/immun;
Nausea: 2 hours after shot, intense at night and the morning after injection Chills: 2 hours after shot, lasted a day and a half Vomiting: morning after injection   Headache: started 2-3 hours after injection until 2 days later Sore Joints, specifically knees: when walking day after injection  soreness at injection site: evening after injection to three days out
Tested positive for COVID-19; Sweating; Coughing; Headache; Pain in arm; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Tested positive for COVID-19), HYPERHIDROSIS (Sweating), COUGH (Coughing), VACCINATION SITE PAIN (Pain in arm) and HEADACHE (Headache) in a 38-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Apr-2021, the patient experienced VACCINATION SITE PAIN (Pain in arm). On 13-Apr-2021, the patient experienced HYPERHIDROSIS (Sweating), COUGH (Coughing) and HEADACHE (Headache). On 19-Apr-2021, the patient experienced COVID-19 (Tested positive for COVID-19). At the time of the report, COVID-19 (Tested positive for COVID-19), HYPERHIDROSIS (Sweating), COUGH (Coughing), VACCINATION SITE PAIN (Pain in arm) and HEADACHE (Headache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 19-Apr-2021, SARS-CoV-2 test: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.  Treatment information was not provided.
Light headed, weak, chills, temp 101, soreness in arm, took ADVIL to eliminate fever 200 mg. Went away as quickly as it came on, gone by afternoon. Now she is doing well.
Site: Redness at Injection Site-Severe, Site: Swelling at Injection Site-Severe, Systemic: blisters at injection site-Severe, Additional Details: Patient presented on 9/16/21 with redness and blisters on her right arm.  She says the injection site started "burning" about 5 to 6 hours after the injection on 9/14/21.  She visited urgent care on 9/16/21.  She claims the doctor diagnosed her with "second degree burn".
Started having chest pain, on 10/21/2022.  Finally went to the hospital on 10/28/2022.  Spent 24 hours there, and had a cardiac workup.  Symptoms were deep, sharp, left-sided chest pain, intermittent throughout the day, and consistant at night, when lying down.
enormous red rash; This case was reported by a consumer via interactive digital media and described the occurrence of red rash in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 21st August 2020, the patient received Shingrix. In August 2020, less than a week after receiving Shingrix, the patient experienced red rash. On an unknown date, the outcome of the red rash was unknown.   It was unknown if the reporter considered the red rash to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but it was selected as adult as per the vaccine indication. The patient received Shingrix and developed an enormous red rash.
shingles; Information has been received from a lawyer referring to a male patient of unknown age. Information about concurrent condition, history condition and concomitant medication was not reported. On or around 16-JAN-2014, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (strength, dose, route, lot# and expiration date unknown) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). Shortly after receiving zoster vaccine live (ZOSTAVAX), the patient suffered a severe painful rash on his back and was diagnosed as shingles. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient's symptoms have resulted in physical limitations not present prior to using the vaccine. The patient also experiences mental and emotional distress due to resulting physical limitations and seriousness of his condition. As a result of the manufacture, marketing, advertising, promotion, distribution and/or sale of zoster vaccine live (ZOSTAVAX), the patient sustained severe and permanent personal injuries. Further, as a tragic consequence of zoster vaccine live (ZOSTAVAX), the patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient has suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of the event shingles was considered to be not recovered and causal relationship was assessed as related.   The lawyer considered the event shingles to be disability.
No additional adverse effects reported; patient was administered a dose of properly stored but expired PEDVAXHIB; This spontaneous report as received from a registered nurse refers to a 12-month old female patient. Information regarding the patient's concurrent conditions, drug allergies or reactions, and concomitant medications was not provided.   On 14-APR-2020 the patient was vaccinated with a properly stored but expired dose of haemophilus b conjugate vaccine (meningococcal protein conjugate)(LIQUID PEDVAXHIB) injection as prophilaxys, lot # N014943 and expiration date 05-MAR-2020 (dose number and frequencyof vaccination scheme, route of administration and anatomical location were not reported). No additional adverse effects were reported.
flu like symptoms; sweaty; clammy; bodyache; fatigue; vomiting; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (flu like symptoms), HYPERHIDROSIS (sweaty), COLD SWEAT (clammy), MYALGIA (bodyache) and FATIGUE (fatigue) in a 91-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included LISINOPRIL, ATENOLOL and CITALOPRAM HYDROCHLORIDE (ELOPRAM [CITALOPRAM HYDROCHLORIDE]) for an unknown indication.   On 10-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On 10-Mar-2021, the patient experienced INFLUENZA LIKE ILLNESS (flu like symptoms), HYPERHIDROSIS (sweaty), COLD SWEAT (clammy), MYALGIA (bodyache), FATIGUE (fatigue) and VOMITING (vomiting). At the time of the report, INFLUENZA LIKE ILLNESS (flu like symptoms), HYPERHIDROSIS (sweaty), COLD SWEAT (clammy), MYALGIA (bodyache) and FATIGUE (fatigue) outcome was unknown.            No treatment information was provided
Information has been received from a registered nurse regarding a patient of an unknown age and gender. On 01-JUL-2013 at 07:40, ZOSTAVAX lot # J001005 was exposed to an exact T not recorded but noted as equal to or > 12C for an estimated total time out of range of 44.5 hours. On 01-JUL-2013, the patient was vaccinated with an out of range dose of ZOSTAVAX (dose and route administration were not provided) (Lot number J001005, Exp. Date: 24-APR-2014). No adverse experience had been reported. This is one of 182 reports from the same source. Additional information has been requested.
Admin injection to LA IM at 10:30am; at 10:55am LA: noted 3cm hard swollen area at injection site. No signs/symptoms noted of any resp distress. Scheduled with Dr. for further evaluation and final disposition.
I had the Moderma COVID-19 vaccine and now I am having a fever 100.8 and body aches
shingrix second dose was given only 25 days after initial dose, first doe 8/22/21, second dose 9/16/21
(L) arm pain, swelling, mild fever, chills (L) arm 3 cm induration w/ mild erythema and slight heat. No nodes, no D/C or streaks.
PT recd series of 3 Engerix-B vax (20mcg) on 14MAR90, 14APR90, & 16SEP90; 7NOV90 test indicated PT was a low responder; recd 2 more doses on 20JAN91 & 10MAR91; 30MAY91 tested pos for Abs;
Patient was taken to ER with symptoms of vomiting. Mother states patient was given Zofran in ER and has not thrown up since. Mother states patient is doing better this morning.
raised red rash at site of injection aprox size of an avacado, warm & tender to touch, +  persistent mild to moderate genital itching
Immediately following the shot, I was very dizzy. I remained for 30 minutes for monitoring. The dizziness continued throughout the day (11/30/21). At 6:00am on 12/1/21, I started to experience severe vertigo. The entire room was spinning. I felt that I could not take more than a step or two without feeling that i was going to faint. This vertigo continued through most of the day into the evening. It dissipated after 12/1/21; however the dizziness (mild) continued through 12/02/2021.
This spontaneous report was received from a certified medical assistant concerning a patient of unknown age and gender. On an unknown date in September 2011, the patient was vaccinated with the first dose of, 0.5 milliliter (ml) of GARDASIL (lot number and expiry date unspecified), intramuscularly. On an unknown date in January 2012, the patient was vaccinated with the second dose of, 0.5 ml of GARDASIL (lot number and expiry date unspecified), intramuscularly. On an unknown date in October 2012, the patient was vaccinated with the third dose of, 0.5 ml of GARDASIL (lot number and expiry date unspecified), intramuscularly. On 10-AUG-2013, the patient was vaccinated with an extra dose of, 0.5 ml of GARDASIL (lot number and expiry date unspecified), intramuscularly. No concomitant therapy was reported. No adverse effect was reported. Additional information has been requested.
This spontaneous report was received from a physician refers to a patient of unknown age and gender. The patient's medical history, drug reactions/allergies and concomitant medications were not reported. On 24-AUG-2016, the patient was vaccinated with improperly stored (Oka/Merck) PROQUAD, rHA, lot # M019232, expiry date 17-OCT-2017, 0.5 ml. Vaccine was exposed to a maximum of 9F and a minimum of 6.8F for a cumulative time frame out of recommended storage range for 23 hours. Data logger in use yes. On 24-AUG-2016, the patient was vaccinated with (wistar ra 27-3) M-M-R II, rHA, (lot # L030162, expiry date 11-AUG-2017), intramuscularly instead of subcutaneously, 0.5 ml. No adverse effects reported. The outcome of the events was unknown. No product quality complaint (PQC) was involved. No further information provided. This is one of several reports received from the same reporter. Additional information has been requested.
Pt felt dizzy, "heavy body", lightheaded, slightly nauseous at times. EMTs were called, checked vitals (all were okay), she chose to not leave in ambulance, was advised not to drive home so husband came to pick her up. She was counseled on monitoring symptoms if she felt she needed to go to hospital later. Signed waiver with EMTs
Swollen Lymph node in right arm. Terrible pain in my lymph node and shoulder. Still have pain on the second day. Terrible migraine for an entire day.
For several days, I had numbness on the left side of my face, left eyelid drooping and corner of left side of mouth.  Also very teary and strained eyes.  Went to ER, thought it was a stroke, was diagnosed as Bells Palsy.  Treated with steroid and artificial tears  for eyes.  Disappeared in 4 days.
dizziness; arm hurting; felt extreme discomfort; nausea; feeling sick; fatigue; headache; rapid pulse; she was in bed 13Feb21 to 15Feb21 feeling sick; This is a spontaneous report from a contactable consumer (patient, self-reported). A 73-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTEC COVID-19 mRNA VACCINE, Solution for injection, lot number: EN6210 and expiry date was not reported), via an unspecified route of administration, in Arm Left, on 12Feb2021 (age at vaccination: 73 years), as a single dose for COVID-19 immunization. The patient's medical history included diabetic, renal problems, and chronic back problems. Concomitant medications included insulin and dulaglutide (TRULICITY) both for diabetic. The patient experienced side effects such as nausea, headache, fatigue, dizziness, arm hurting the next day. She stated that she also experienced having a rapid pulse yesterday on 16Feb2021 which was a week after getting the vaccine and wanted to know if it's still ok for her to get the 2nd dose since she experienced these side effects and if having a rapid pulse was one of the normal side effects from the vaccine. Also wanted to know if there were any known interactions of the vaccine with insulin or Trulicity since she mentioned that she took Trulicity last Saturday morning and noticed that she experienced a rapid pulse the day after. The patient also felt extreme discomfort and an elevated heart rate and stated she was in bed 13Feb2021 to 15Feb2021 feeling sick. She felt better then was sick again on Sunday. The patient underwent lab tests and procedures which included glomerular filtration rate: 44 on an unspecified date in Dec2020 and heart rate increased: 119 to 120 on 22Feb2021 (Pulse rapid). The patient stated that they did not give her a second dose date. Outcome of the event she was in bed 13Feb21 to 15Feb21 feeling sick was recovered on 15Feb2021 and for all other events, it was unknown.  No follow-up attempts are possible. No further information is expected.
It started with some soreness of my arm (similar to a flu shot) and a lump under my skin at site of injection. The bump started to feel warm to the touch & red. The bump became more prominent & swollen as the redness spread to about 2-2.5 inch diameter. It is the end of Day 3 right now since the vaccine was administered and the symptoms are still present but not getting worse.
Injection site swollen, injection site on arm very sore to touch, hurts to move arm at all,  face, lips, nose are numb and tingling, face swollen (very swollen),  weak, nauseated, dizzy
Vials of Menveo vaccine came from the manufacturer with 2 different lot number on the vial.
He was lethargic, diarrhea for a couple of days, a little warm, loss of appetite, and fussy. We went to the doctor and they tested him for flu and COVID-19. They both were positive. We gave him Tylenol and Motrin.